Comparison · NCT03382899-sae
Pegilodecakin + Pembrolizumab vs Pembrolizumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pegilodecakin + Pembrolizumab vs Pembrolizumab: serious adverse events. Trial comparisons, record NCT03382899-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03382899-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.56 | 0.423 | 0.688 | wilson | |
| Risk in group 2 | 0.521 | 0.383 | 0.655 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0392 | -0.153 | 0.227 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.746 | 1.55 | log | |
| Odds ratio, group 1 over group 2 | 1.17 | 0.529 | 2.59 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Pegilodecakin + Pembrolizumab than on Pembrolizumab | 25.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pegilodecakin + Pembrolizumab | Participants received pegilodecakin SQ at 0.8 mg (≤80 kg body weight) or 1.6 mg (\>80 kg body weight) QD in the abdomen, thigh or back of upper arm.~Pembrolizumab administered as an IV infusion at 200 mg on Day 1 of a 21-day cycle. | 28 | 50 | EG000 |
| Group 2 | Pembrolizumab | Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle. | 25 | 48 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline Up To 24 Months
Source ClinicalTrials.gov
Trial
- Title
- Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
- NCT number
- NCT03382899
- Phases
- PHASE2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pegilodecakin, Pembrolizumab
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2021-01-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03382899?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03382899-sae